B-cell-intrinsic hepatitis C virus expression leads to B-cell- lymphomagenesis and induction of NF-κB signalling

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Kasama, Yuri ^a   Mizukami, Takuo ^b   Kusunoki, Hideki ^b   Peveling Oberhag, Jan ^c   Nishito, Yasumasa ^d   Ozawa, Makoto ^e   Kohara, Michinori ^d   Mizuochi, Toshiaki ^b   Tsukiyama Kohara, Kyoko ^e  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 26B; UNCLASSIFIED DRUG; MIRN26 MICRORNA, MOUSE; TRANSCRIPTION FACTOR RELA; TUMOR PROTEIN;

A20 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; C3 GENE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FOS GENE; GENE; GENE EXPRESSION PROFILING; HEPATITIS C VIRUS; LTBR GENE; MALE; MOUSE; NF KB GENE; NONHUMAN; SEX DIFFERENCE; SIGNAL TRANSDUCTION; VIRUS CARCINOGENESIS; VIRUS EXPRESSION; VIRUS GENOME; ANIMAL; CELL NUCLEUS; COMPUTER PROGRAM; DNA MICROARRAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; HEPATITIS C; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; TRANSGENIC MOUSE; VIROLOGY;

ANIMALS; B-LYMPHOCYTES; CELL NUCLEUS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPACIVIRUS; HEPATITIS C; LYMPHOMA, B-CELL; MICE, TRANSGENIC; MICRORNAS; NEOPLASM PROTEINS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SOFTWARE; TRANSCRIPTION FACTOR RELA;

EID: 84922479279     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091373     Document Type: Article

References (73)

1. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567. (Pubitemid 41196755)
2. Libra M, Gasparotto D, Gloghini A, Navolanic PM, De Re V, et al. (2005) Hepatitis C virus (HCV) I hepatitis C virus (HCV) infection and lymphoproliferative disorders. Front Biosci 10: 2460-2471. (Pubitemid 40905250)
3. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, et al. (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 87: 6547-6549.
4. Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, et al. (1996) Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 87: 4296-4301. (Pubitemid 26152271)
5. Ascoli V, Lo Coco F, Artini M, Levrero M, Martelli M, et al. (1998) Extranodal lymphomas associated with hepatitis C virus infection. Am J Clin Pathol 109: 600-609. (Pubitemid 28191550)
6. Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, et al. (2003) Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 102: 996-999. (Pubitemid 36917795)
7. Ito M, Kusunoki H, Mizuochi T (2011) Peripheral B cells as reservoirs for persistent HCV infection. Front Microbiol 2: 177.
8. Dammacco F, Sansonno D, Piccoli C, Racanelli V, D'Amore FP, et al. (2000) The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin Liver Dis 20: 143-157. (Pubitemid 30618713)
9. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S (2013) Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 59: 169-177.
10. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, et al. (2002) Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347: 89-94. (Pubitemid 34753478)
11. Hess J, Angel P, Schorpp-Kistner M (2004) AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117: 5965-5973. (Pubitemid 40123963)
12. Vasanwala FH, Kusam S, Toney LM, Dent AL (2002) Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol 169: 1922-1929. (Pubitemid 34857655)
13. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, et al. (2008) Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A 105: 19643-19648.
14. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl: S81-96.
15. Sen R, Baltimore D (1986) Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47: 921-928. (Pubitemid 17005065)
16. Bakkar N, Guttridge DC (2010) NF-kappaB signaling: a tale of two pathways in skeletal myogenesis. Physiol Rev 90: 495-511.
17. Sun B, Karin M (2008) NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 27: 6228-6244.
18. Arsura M, Cavin LG (2005) Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 229: 157-169.
19. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, et al. (2009) A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16: 295-308.
20. De Re V, Caggiari L, Garziera M, De Zorzi M, Repetto O (2012) Molecular signature in HCV-positive lymphomas. Clin Dev Immunol 2012: 623465.
21. Opipari AW, Jr., Boguski MS, Dixit VM (1990) The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 265: 14705-14708.
22. Song HY, Rothe M, Goeddel DV (1996) The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci U S A 93: 6721-6725. (Pubitemid 26230376)
23. Lee EG, Boone DL, Chai S, Libby SL, Chien M, et al. (2000) Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289: 2350-2354.
24. Heyninck K, Beyaert R (2005) A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions. Trends Biochem Sci 30: 1-4. (Pubitemid 40093732)
25. Malynn BA, Ma A (2009) A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme. J Exp Med 206: 977-980.
26. Hymowitz SG, Wertz IE (2010) A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer 10: 332-341.
27. Kato M, Sanada M, Kato I, Sato Y, Takita J, et al. (2009) Frequent inactivation of A20 in B-cell lymphomas. Nature 459: 712-716.
28. Honma K, Tsuzuki S, Nakagawa M, Karnan S, Aizawa Y, et al. (2008) TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosomes Cancer 47: 1-7. (Pubitemid 350191458)
29. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, et al. (2009) TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 114: 2467-2475.
30. Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, et al. (2009) TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 206: 981-989.
31. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, et al. (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459: 717-721.
32. Parvatiyar K, Barber GN, Harhaj EW (2010) TAX1BP1 and A20 inhibit antiviral signaling by targeting TBK1-IKKi kinases. J Biol Chem 285: 14999-15009.
33. Parvatiyar K, Harhaj EW (2011) Regulation of inflammatory and antiviral signaling by A20. Microbes Infect 13: 209-215.
34. Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, et al. (2010) The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 33: 181-191.
35. Verstrepen L, Verhelst K, van Loo G, Carpentier I, Ley SC, et al. (2010) Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol 80: 2009-2020.
36. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531. (Pubitemid 38868508)
37. Lawrie CH (2007) MicroRNA expression in lymphoma. Expert Opin Biol Ther 7: 1363-1374. (Pubitemid 47485149)
38. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309: 1577-1581. (Pubitemid 41266486)
39. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, et al. (2012) MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A 109: 7865-7870.
40. Hother C, Rasmussen PK, Joshi T, Reker D, Ralfkiaer U, et al. (2013) MicroRNA Profiling in Ocular Adnexal Lymphoma: A Role for MYC and NFKB1 Mediated Dysregulation of MicroRNA Expression in Aggressive Disease. Invest Ophthalmol Vis Sci 54: 5169-5175.
41. Peveling-Oberhag J, Crisman G, Schmidt A, Doring C, Lucioni M, et al. (2012) Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia 26: 1654-1662.
42. Fognani E, Giannini C, Piluso A, Gragnani L, Monti M, et al. (2013) Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemia. PLoS One 8: e62965.
43. Kasama Y, Sekiguchi S, Saito M, Tanaka K, Satoh M, et al. (2010) Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 116: 4926-4933.
44. Tsukiyama-Kohara K, Tone S, Maruyama I, Inoue K, Katsume A, et al. (2004) Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells. J Biol Chem 279: 14531-14541. (Pubitemid 38618840)
45. Rickert RC, Roes J, Rajewsky K (1997) B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res 25: 1317-1318. (Pubitemid 27303232)
46. Nishimura T, Kohara M, Izumi K, Kasama Y, Hirata Y, et al. (2009) Hepatitis C virus impairs p53 via persistent overexpression of 3beta-hydroxysterol Delta24-reductase. J Biol Chem 284: 36442-36452.
47. Yamazaki J, Mizukami T, Takizawa K, Kuramitsu M, Momose H, et al. (2009) Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma. Blood 114: 2709-2720.
48. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R (2003) Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 125: 1723-1732. (Pubitemid 37500437)
49. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, et al. (2004) Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 95: 745-752. (Pubitemid 39335095)
50. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, et al. (2008) Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 6: 451-458. (Pubitemid 351447318)
51. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361: 1437-1447.
52. Ji Y, He Y, Liu L, Zhong X (2010) MiRNA-26b regulates the expression of cyclooxygenase-2 in desferrioxamine-treated CNE cells. FEBS Lett 584: 961-967.
53. Gao W, Shen H, Liu L, Xu J, Xu J, et al. (2011) MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 137: 557-566.
54. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, et al. (2008) Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res 14: 2588-2592.
55. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, et al. (2002) Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 21: 4104-4113. (Pubitemid 34857442)
56. Szremska AP, Kenner L, Weisz E, Ott RG, Passegue E, et al. (2003) JunB inhibits proliferation and transformation in B-lymphoid cells. Blood 102: 4159-4165. (Pubitemid 37487003)
57. Bassig BA, Zheng T, Zhang Y, Berndt SI, Holford TR, et al. (2012) Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma. Environ Mol Mutagen 53: 145-151.
58. Andoh A, Fujiyama Y, Hata K, Araki Y, Takaya H, et al. (1999) Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clin Exp Immunol 118: 23-29. (Pubitemid 29479779)
59. Fischer WH, Jagels MA, Hugli TE (1999) Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). J Immunol 162: 453-459. (Pubitemid 29018953)
60. Matsumoto M, Hsieh TY, Zhu N, VanArsdale T, Hwang SB, et al. (1997) Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol 71: 1301-1309. (Pubitemid 27030304)
61. Chen CM, You LR, Hwang LH, Lee YH (1997) Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. J Virol 71: 9417-9426.
62. You LR, Chen CM, Lee YH (1999) Hepatitis C virus core protein enhances NF-kappaB signal pathway triggering by lymphotoxin-beta receptor ligand and tumor necrosis factor alpha. J Virol 73: 1672-1681.
63. Simonin Y, Vegna S, Akkari L, Gregoire D, Antoine E, et al. (2013) Lymphotoxin Signaling Is Initiated by the Viral Polymerase in HCV-linked Tumorigenesis. PLoS Pathog 9: e1003234.
64. Vladareanu AM, Ciufu C, Neagu AM, Onisai M, Bumbea H, et al. (2010) The impact of hepatitis viruses on chronic lymphoproliferative disorders-preliminary results. J Med Life 3: 320-329.
65. Heyninck K, De Valck D, Vanden Berghe W, Van Criekinge W, Contreras R, et al. (1999) The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol 145: 1471-1482. (Pubitemid 29310004)
66. Dondelinger Y, Aguileta MA, Goossens V, Dubuisson C, Grootjans S, et al. (2013) RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ 20: 1381-1392.
67. Cai X, Du J, Liu Y, Xia W, Liu J, et al. (2013) Identification and characterization of receptor-interacting protein 2 as a TNFR-associated factor 3 binding partner. Gene 517: 205-211.
68. Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, et al. (2012) MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 40: 4615-4625.
69. Ma YL, Zhang P, Wang F, Moyer MP, Yang JJ, et al. (2011) Human embryonic stem cells and metastatic colorectal cancer cells shared the common endogenous human microRNA-26b. J Cell Mol Med 15: 1941-1954.
70. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, et al. (2011) Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2: 669-683.
71. Song G, Xu G, Ji C, Shi C, Shen Y, et al. (2014) The role of microRNA-26b in human adipocyte differentiation and proliferation. Gene 533: 481-487.
72. Palumbo T, Faucz FR, Azevedo M, Xekouki P, Iliopoulos D, et al. (2013) Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene 32: 1651-1659.
73. Tsukiyama-Kohara K, Poulin F, Kohara M, DeMaria CT, Cheng A, et al. (2001) Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat Med 7: 1128-1132. (Pubitemid 33010021)